Cover Image
市場調查報告書

頭頸椎鱗狀細胞癌 (HNSCC) :KOL的洞察

Head and Neck Squamous Cell Carcinoma: KOL Insight

出版商 FirstWord 商品編碼 354929
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
頭頸椎鱗狀細胞癌 (HNSCC) :KOL的洞察 Head and Neck Squamous Cell Carcinoma: KOL Insight
出版日期: 2016年03月01日 內容資訊: 英文
簡介

本報告以頭頸椎鱗狀細胞癌 (HNSCC) 為主題,提供北美、歐洲的KOL的見解,上市藥、開發平台藥物詳細調查。

調查目標產品

  • EGFR抑制劑
    • Erbitux (cetuximab; Eli Lilly/Merck)
    • Gilotrif/Giotrif (afatinib; Boehringer Ingelheim)
    • Tarceva (erlotinib; Astellas/Roche)
  • 免疫治療藥
    • Durvalumab (MEDI4736; AstraZeneca)
    • Keytruda (pembrolizumab; Merck & Co.)
    • Multikine (Leukocyte interleukin, CEL-SCI)
    • Opdivo (nivolumab; Bristol-Myers Squibb)
  • 其他的治療藥物
    • Avastin (bevacizumab; Genentech/Roche)
    • Reolysin (pelareorep; Oncolytics Biotech)

要點

  • 免疫療法轉換成HNSCC治療
  • 圍繞首位的競爭
  • 大膽的商業策略
  • 臨床實驗鑰匙
  • 預計Erbitux 的使用變化
  • 新的EGFR抑制劑的困難市場
  • 對其他方法的保守的期待
  • 初期的生物標記

調查的主要課題

  • 未滿足需求
  • KOL歡迎的免疫療法
  • 商用 vs. 醫療用
  • 一線免疫療法
  • 聯合治療
  • 定做療法
  • 成本檢討事項

關鍵意見領袖 (KOL)

  • 北美
  • 歐洲
目錄
Product Code: 596200543

Immunotherapies are about to transform HNSCC treatment. Can one brand corner the market?

Key opinion leaders (KOLs) say immunotherapies will transform head and neck squamous cell carcinoma (HNSCC) treatment. But until Phase III trial results are in, no one knows exactly where these promising new drugs will fit into the treatment algorithm-and whether any one brand can corner the market.

Find out what KOLs think in FirstWord's new report, KOL Insight: HNSCC

You'll find out how immunotherapies are likely to be used, how they'll affect current treatments, and whether they'll face competition from targeted agents in the pipeline. You'll also get KOLs' candid thoughts on the important clinical trials shaping HNSCC treatment and prescribing.

Plus: Order the report today and you'll receive three quarterly FirstWord Therapy Trends Update Bulletins absolutely free!

Marketed drugs covered:

  • Erbitux (cetuximab; Eli Lilly/Merck)

Pipeline drugs covered:

  • Avastin (bevacizumab; Genentech/Roche)
  • Durvalumab (MEDI4736; AstraZeneca)
  • Gilotrif/Giotrif (afatinib; Boehringer Ingelheim)
  • Keytruda (pembrolizumab; Merck & Co.)
  • Multikine (Leukocyte interleukin, CEL-SCI)
  • Opdivo (nivolumab; Bristol-Myers Squibb)
  • Reolysin (pelareorep; Oncolytics Biotech)
  • Tarceva (erlotinib; Astellas/Roche)
Back to Top